The Arizona Legislature appropriated up to $5,000,000 beginning in fiscal year 2025-2026 to fund phase one (1), two (2), and/or three (3) clinical trials. This funding will run for five (5) years from the date of award and is exempt from lapsing.
RFGA 2026-006 Ibogaine Research Clinical Trials Grant
Solicitation Period: October 3, 2025 through November 19, 2025
The Arizona Biomedical Research Centre (ABRC), through the Arizona Department of Health Services (ADHS), announces that a Request for Grant Applications (RFGA) solicitation process has opened. This announcement serves as the notice required pursuant to by Laws 2025, Chapter 233 (57th Leg 1st Reg), SB 1735, Sec 43. (https://www.azleg.gov/legtext/57leg/1R/laws/0233.pdf). Applications can be submitted until 3:00 p.m. November 19, 2025. Access to the funding opportunity can be found at https://grants.az.gov/funding-opportunities. Applications can be submitted using the eCivis Grant Portal. Applicants must establish an account on the eCivis portal through the following website: https://portal.ecivis.com. Questions regarding this grant opportunity can be sent to:
Brittany Manuel
Senior Procurement Specialist
Arizona Dept of Health Services
Brittany.Manuel@azdhs.gov
The Arizona Legislature appropriated up to $5,000,000 beginning in fiscal year 2025-2026 to fund phase one (1), two (2), and/or three (3) clinical trials. This funding will run for five (5) years from the date of award and is exempt from lapsing.
The total amount to be awarded under this grant program is subject to availability of funds, future continuing appropriations, and the decision of the ABRC. ADHS shall not be obligated to select project proposals to cover the full amount of available funding and reserves the right to cancel the RFGA without awarding any grant funds.
Research projects shall present value in answering the research questions in a manner that benefits Arizonans. Research projects supported include those that are aimed specifically at evaluating the safety and efficacy of ibogaine usage by humans. Research projects supported include randomized controlled clinical trials that study the treatment of neurological diseases.
Eligible applicants shall have the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) are eligible to apply for this Grant. They shall hold an independent research position at a domestic (U.S.) institution. For the purpose of this RFGA: “Independent research position” means a position that automatically confers eligibility, by the applicant’s institutional policy, for an investigator to apply for NIH R01 grants, with an appropriate commitment of facilities to be used for the conduct of the proposed research. The Principal Investigator (PI) shall reside in Arizona. The lead institution shall originate in Arizona; have a history of proven research and treatment of neurological diseases; have a neurosurgery program with the requisite clinical and research facilities and that is staffed by professionals having expertise in the most challenging neurological and neurosurgical conditions; have the ability to facilitate pioneering research and innovation in diagnosis and treatment of neurological conditions; and be publishable in peer-reviewed medical and public health journals.
The department will award a grant only to an entity that satisfies all of the following: has a history of proven research and treatment of neurological diseases; has a neurosurgery program with the requisite clinical and research facilities and that is staffed by professionals having expertise in the most challenging neurological and neurosurgical conditions; and has the ability to facilitate pioneering research and innovation in diagnosis and treatment of neurological conditions.
Current ABRC Grant recipients may apply for the Ibogaine Clinical Research Grant as long as the Eligibility criteria is met.
For more information about the Ibogaine Research Program
contact the Arizona Biomedical Research Centre
at biomedical@azdhs.gov.